XERS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Xeris Biopharma Holdings Inc (XERS) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company shows growth in revenue and a strong product pipeline, its negative net income, declining EPS, and weak technical indicators suggest limited immediate upside. The stock's recent price trend and lack of strong trading signals further support a hold recommendation.
The MACD is negatively expanding (-0.0413), RSI is neutral (29.623), and moving averages are converging, indicating no clear trend. The stock is trading below the pivot level of 6.811, with key support at 6.429 and resistance at 7.193. Overall, the technical indicators suggest a bearish or neutral trend.
Barclays initiated coverage with an Overweight rating and a $9 price target, citing improving investor sentiment and easing pricing headwinds in the specialty pharmaceuticals sector. The company has a strong product pipeline with three commercially available products and multiple development programs.
The stock is expected to decline in the short term, with a 70% chance of a -2.7% drop in the next day and -0.87% in the next week. Financial performance shows a significant drop in net income (-103.95% YoY) and EPS (-100% YoY). Technical indicators are weak, and there are no significant trading trends from hedge funds or insiders.
In Q3 2025, revenue increased by 37.06% YoY to $74.38M, and gross margin improved to 81.57% (up 16.60% YoY). However, net income dropped by -103.95% YoY to $621K, and EPS fell to 0, indicating profitability challenges.
Barclays initiated coverage with an Overweight rating and a $9 price target, reflecting optimism about the company's innovation and margin expansion potential. However, the stock remains in a transitional phase with no immediate catalysts for significant growth.
